Circulating microRNAs as emerging non-invasive biomarkers for gliomas

Santangelo, A; Tamanini, Anna; Cabrini, Giulio; Dechecchi, Maria Cristina

doi:10.21037/atm.2017.06.15

Cited by 32 publications

(24 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the last few years, great effort has been put into searching for diagnostic, prognostic, predictive, and therapeutic response biomarkers in glioma patients [16]; however, so far, no single circulating biomarker has been used in routine practice for management of these patients [17]. The search for these kinds of biomarkers still represents an exciting research area; therefore, the aim of the current study was the evaluation of serum and CSF concentrations of CCL2, IL-8, and ICAM-1 in patients with neuroepithelial tissue tumors as compared to non-tumoral patients, with no history of cancer as a comparative group.…”

Section: Introductionmentioning

confidence: 99%

Cerebrospinal fluid and serum IL-8, CCL2, and ICAM-1 concentrations in astrocytic brain tumor patients

et al. 2017

View full text Add to dashboard Cite

Background The aim of the study was the evaluation of serum and CSF concentrations of CCL2, IL-8, and sICAM-1 in patients with astrocytic tumors as compared to a group of non-tumoral patients. Methods Chemokine concentrations were measured using the ELISA method.Results Regardless of the parameter tested and the patient group (brain tumor or non-tumoral patients), statistical differences (P < 0.05) were found between concentrations obtained in CSF compared to values obtained in serum for all proteins tested. CSF IL-8 concentrations were significantly elevated in CNS tumor patients as compared to non-tumoral individuals (P = 0.000); serum CCL2 and sICAM-1 concentrations were significantly decreased in CNS tumors in comparison with the comparative group (P = 0.002 and P = 0.026, respectively). Among proteins tested in the serum, a higher area under the ROC curve (AUC) revealed CCL2 compared to sICAM-1 in differentiating subjects with CNS brain tumors from nontumoral subjects. AUC for CSF IL-8 was higher than for its index (CSF IL-8/serum IL-8).Conclusions For individual biomarkers (IL-8 and CCL2, sICAM-1), measured in CNS brain tumor patients, the appropriate material, respectively CSF or serum, should be chosen and quantitatively tested. Increased cerebrospinal fluid IL-8 with decreased serum CCL2 create a pattern of biomarkers, which may be helpful in the management of CNS astrocytic brain tumors.

show abstract

Section: Introductionmentioning

confidence: 99%

Cerebrospinal fluid and serum IL-8, CCL2, and ICAM-1 concentrations in astrocytic brain tumor patients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…MiR146a and miR26a were upregulated in the vitreous humor of uveal melanoma patients [ 16 ], and follow-up studies revealed miR146a was also upregulated in blood serum exosomes of uveal melanoma patients [ 17 ]. Additionally, systemic miRNAs are being investigated as biomarkers for malignant gliomas [ 18 ]. In brain tissue, miRNA expression is up- or downregulated for numerous miRNA with glioma onset and progression, and preliminary clinical data suggests circulating miRNA may serve as a biomarker for glioma diagnosis and prognosis.…”

Section: Evs As Biomarkers In the Visual Systemmentioning

confidence: 99%

Extracellular Vesicles: Biomarkers, Therapeutics, and Vehicles in the Visual System

Merwe

Steketee

2017

Curr Ophthalmol Rep

View full text Add to dashboard Cite

PurposeWe discuss recent advances in extracellular vesicle (EV) technology as biomarkers, therapeutics, and drug delivery vehicles in the visual system with an emphasis on the retina.Recent FindingsRetinal cell-type specific EVs can be detected in the blood and in the aqueous humor and EV miRNA cargoes can be used diagnostically to predict retinal disease progression. Studies have now shown EVs can deliver bioactive miRNA and AAV cargoes to the inner retinal cell layers and, in some models, improve retinal ganglion cell (RGC) survival and axon regeneration.SummaryEV molecular profiles and cargoes are attractive biomarkers for retinal and optic nerve disease and trauma and EVs offer a safe and tunable platform for delivering therapies to ocular tissues. However, EVs are heterogeneous by nature with variable lipid membranes, cargoes, and biologic effects, warranting stringent characterization to understand how heterogeneous EV populations modulate positive tissue remodeling.

show abstract

“…GC is one of the leading causes of cancer-associated mortality due to late diagnosis and limited therapeutic strategies. Circulating miRNAs are promising, noninvasive biomarkers for cancer screening (17). The present study reported an investigation on miR-650 expression in human GC.…”

Section: Discussionmentioning

confidence: 87%

Diagnostic value and clinical significance of circulating miR‑650 and CA211 in detecting of gastric carcinoma

Chen

Sun

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

The present study determined the levels of plasma biomarkers in patients with gastric carcinoma (GC) and investigated their clinical significance and diagnostic value. Between April 2014 and December 2018, 90 patients with GC, 90 patients with precancerous lesions (Pre) and 45 healthy controls (NC) were recruited from the Affiliated Liutie Central Hospital of Guangxi Medical University. Five markers were measured: microRNA-650 (miRNA-650; using reverse transcription-quantitative polymerase chain reaction), and carcinoembryonic antigen (CEA), carbohydrate antigen (CA)125, CA211 and CA50 using electrochemiluminescence. Circulating markers were all upregulated in patients with GC (P<0.05), and CA211 and CA50 were significantly increased in patients with Pre. The miRNA-650 and CA211 had an area under the curve (AUC) of 0.700 (moderate) and 0.866 (high), respectively, in the diagnosis of GC. Differentiation of GC from Pre yielded an AUC of 0.665 (low) and 0.708 (moderate), respectively. The combination model of miRNA-650 and CA211 showed an appropriate value of AUC (0.887) to discriminate the GC patients from the healthy subjects with a sensitivity and specificity of 82.5 and 97.7%. Additionally, differentiating GC from Pre yielded an AUC of 0.767 with a sensitivity of 57.1% and a specificity of 95%, respectively. In terms of clinicopathological features, the expression of miRNA-650 and CA211 in plasma was not associated with the patients' age, sex, Tumor-Node-Metastasis stage, or histological type. In conclusion, plasma miRNA-650 and CA211 is a promising and powerful non-invasive marker for the detection of GC.

show abstract

Circulating microRNAs as emerging non-invasive biomarkers for gliomas

Cited by 32 publications

References 37 publications

Cerebrospinal fluid and serum IL-8, CCL2, and ICAM-1 concentrations in astrocytic brain tumor patients

Cerebrospinal fluid and serum IL-8, CCL2, and ICAM-1 concentrations in astrocytic brain tumor patients

Extracellular Vesicles: Biomarkers, Therapeutics, and Vehicles in the Visual System

Diagnostic value and clinical significance of circulating miR‑650 and CA211 in detecting of gastric carcinoma

Contact Info

Product

Resources

About